• Ambroxol Modulates Nav1.8, TRPV1, and TRPA1 in Neuropathic P

  2026-07-04

  This article analyzes recent in vitro evidence that ambroxol, a common mucolytic, directly modulates Nav1.8 sodium channels as well as TRPV1 and TRPA1 receptors in human sensory neurons. The findings clarify ambroxol’s mechanism as a topical analgesic and frame its relationship to established TRPV1 agonists like (E)-Capsaicin, with implications for future research targeting pain signaling pathways.

• BODIPY 581/591 C11: Next-Generation Lipid Peroxidation Assay

  2026-07-03

  Explore how BODIPY 581/591 C11, a ratiometric fluorescent probe, advances lipid peroxidation detection and antioxidant evaluation. This article uniquely bridges mechanistic insights from single-atom nanozyme research to practical assay optimization.

• DeferoxamineB: Next-Gen Strategies for Ferroptosis & Cupropt

  2026-07-03

  Explore how Deferoxamine (DeferoxamineB) is redefining cancer research through advanced modulation of ferroptosis and cuproptosis. This thought-leadership article provides mechanistic insights, protocol guidance, and strategic context for translational scientists seeking to harness this iron chelator in regulated cell death and immunometabolic intervention. We connect the latest findings in metabolic sensitization with practical workflows, highlight APExBIO’s product advantages, and chart future directions for oncology and beyond.

• BAPTA Calcium Chelator: Applied Workflows for Apoptosis Rese

  2026-07-02

  BAPTA enables precise modulation of intracellular calcium, transforming how cell biologists dissect apoptosis and calcium signaling under environmental stress. This guide details experimental workflows and troubleshooting strategies, directly informed by the latest mechanistic research and advanced by APExBIO's high-purity offering.

• Dasatinib Monohydrate: Transforming Tumor Assembloid Researc

  2026-07-02

  Dasatinib Monohydrate (BMS-354825) empowers researchers to dissect drug resistance and kinase signaling in complex tumor assembloid models. This guide details optimized workflows, protocol parameters, and troubleshooting strategies for leveraging Dasatinib in physiologically relevant cancer research.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf

  2026-07-01

  EPI-001 empowers researchers to inhibit both full-length and splice variant androgen receptors, unlocking new strategies for prostate and triple-negative breast cancer models. Its unique N-terminal targeting overcomes resistance seen with ligand-binding domain inhibitors, enabling robust, translational workflows.

• Rucaparib (AG-014699): Strategic Advances in DNA Repair Disr

  2026-07-01

  Explore how Rucaparib (AG-014699, PF-01367338) is redefining DNA damage response research. This article integrates mechanistic insights, the latest translational findings—including Pol II degradation pathways—and strategic guidance for researchers leveraging PARP inhibition to interrogate synthetic lethality, radiosensitization, and cancer cell fate. Informed by recent studies and advanced protocols, this perspective positions Rucaparib as an indispensable tool for next-generation cancer biology.

• PDK4-IN-1 Hydrochloride: Reliable PDK4 Inhibition for Cell A

  2026-06-30

  This article addresses common laboratory challenges in metabolic and cell viability assays, showcasing how PDK4-IN-1 hydrochloride (SKU C8760) delivers reproducible, selective PDK4 inhibition. Drawing on peer-reviewed data and practical scenarios, it guides researchers in optimizing protocols and interpreting results when probing mitochondrial energy metabolism.

• Ellagic Acid: Precision CK2 Inhibition in Cancer Biology Res

  2026-06-30

  Ellagic acid offers researchers a selective, ATP-competitive approach to interrogating casein kinase 2 signaling and apoptosis in cancer and senescence models. This guide details optimized workflows, practical troubleshooting, and the latest AI-powered insights for deploying ellagic acid in advanced biochemical and cellular assays.

• Safe DNA Gel Stain: Reliable Data and Workflow Solutions

  2026-06-29

  This article explores how Safe DNA Gel Stain (SKU A8743) addresses persistent laboratory challenges in nucleic acid visualization, offering enhanced sensitivity, reduced mutagenicity, and workflow safety. Readers will find scenario-driven, evidence-based guidance for integrating this DNA and RNA gel stain into high-impact molecular biology protocols.

• Lysis Buffer: Optimizing Rapid Genotyping Kit Components for

  2026-06-29

  APExBIO’s lysis buffer streamlines rapid genotyping workflows by ensuring high-yield, intact genomic DNA extraction from mouse tissues. Explore protocol enhancements, troubleshooting, and comparative evidence to maximize assay reliability and accelerate genetic research in mouse models.

• Chloramphenicol in Plasmid Selection: Protocols & Troublesho

  2026-06-28

  Chloramphenicol sets the gold standard for high-fidelity plasmid selection and antimicrobial screening in molecular biology, thanks to its precise inhibition of bacterial protein synthesis. This article delivers actionable protocols, advanced assay strategies, and troubleshooting insights—directly informed by recent resistance gene transmission studies.

• Optimized Sulfonamides for TB: Reduced CYP 2C9 Inhibition Ac

  2026-06-27

  This study details the rational design of sulfaphenazole-derived sulfonamides with potent antimycobacterial activity and markedly reduced CYP 2C9 inhibition. The findings advance safer tuberculosis therapies and provide a framework for optimizing bioactive compounds with minimized drug-drug interaction risk.

• Annexin V-FITC/PI Apoptosis Assay Kit: Applied Workflows & I

  2026-06-26

  The Annexin V-FITC/PI Apoptosis Assay Kit streamlines early and late apoptosis detection, delivering precise discrimination across challenging cancer and translational models. Discover protocol optimizations, integration strategies, and troubleshooting insights that unlock high-resolution data for modern research.

• DRD4 Drives Chemo-Resistance in Liver Cancer via PI3K/Akt Ax

  2026-06-26

  This study reveals that dopamine receptor D4 (DRD4) promotes chemo-resistance and cancer stem cell-like phenotypes in hepatocellular carcinoma (HCC) by activating the PI3K/Akt/β-catenin pathway. Targeting DRD4 or its downstream signaling offers promising new avenues for overcoming therapeutic resistance in liver cancer.

445 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page